+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infantile Spasms Therapeutics Market - Global Forecast 2026-2032- Product Image
Infantile Spasms Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Infantile Spasms Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904865
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infantile Spasms Therapeutics Market is projected to reach USD 177.00 Million in 2026. It is expected to continue growing at a CAGR of 5.43%, reaching USD 243.73 Million by 2032.

Infantile spasms, now commonly described within infantile epileptic spasms syndrome (IESS), is a rare but severe developmental and epileptic encephalopathy that typically begins in the first year of life. Published epidemiology commonly places incidence at approximately 2 to 3.5 cases per 10,000 live births, making early diagnosis, rapid electroencephalography (EEG), and prompt treatment central to clinical and commercial strategy.

The infantile spasms therapeutics landscape is anchored by hormonal therapy, vigabatrin, and carefully monitored antiseizure regimens, with treatment selection influenced by etiology, access, safety profile, and payer policy. For stakeholders, the market is shaped less by volume and more by urgency, specialist concentration, orphan-disease dynamics, and measurable outcomes such as spasm cessation, EEG improvement, relapse prevention, and neurodevelopmental preservation.

Transformative Shifts in the Therapeutic Landscape

The landscape is shifting from delayed recognition toward time-sensitive care pathways. Pediatric neurologists increasingly emphasize shorter treatment lag because peer-reviewed studies associate faster initiation of effective therapy with improved seizure and developmental outcomes. This is changing referral models across emergency medicine, primary pediatrics, neonatology, pediatric ophthalmology, genetics, and tele-neurology.

Therapeutic strategy is also becoming more etiology-driven. Vigabatrin remains especially important in tuberous sclerosis complex-associated spasms, while adrenocorticotropic hormone and oral corticosteroids remain key hormonal options in many guidelines and clinical practices. At the same time, manufacturers and health systems face persistent pressures around drug cost, formulation access, visual-field safety monitoring for vigabatrin, steroid-related adverse events, treatment adherence, and equitable availability of EEG-confirmed diagnosis.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence infantile spasms therapeutics by strengthening the diagnostic and evidence-generation infrastructure around treatment. AI-enabled video analysis, automated seizure-pattern detection, and EEG decision-support tools are being evaluated to reduce missed spasms and shorten the interval between symptom onset and specialist review.

The cumulative commercial impact is expected to come from better patient identification, more structured real-world evidence, and more efficient trial recruitment rather than from AI replacing clinician judgment. AI can support digital phenotyping, adherence monitoring, pharmacovigilance signal detection, care pathway analytics, and payer evidence packages, but infantile spasms treatment decisions still require pediatric neurology oversight, EEG interpretation, and individualized risk-benefit assessment.

Key Regional Insights

North America remains a leading region for infantile spasms therapeutics because of established pediatric epilepsy centers, high availability of EEG, active clinical research networks, and formal reimbursement mechanisms for approved therapies such as vigabatrin and corticotropin-based treatment. The United States particularly drives evidence generation, clinical trial activity, and specialty pharmacy pathways, while Canada supports access through provincial formularies, pediatric neurology referral systems, and publicly funded hospital infrastructure.

Europe benefits from mature pediatric neurology infrastructure and regulatory oversight through national authorities and the European Medicines Agency, although reimbursement and prescribing pathways vary across the United Kingdom, Germany, France, Italy, Spain, and other national systems. Asia-Pacific is expanding in clinical capability, supported by Japan, China, South Korea, Australia, India, and ASEAN countries, but access remains uneven between metropolitan centers and rural populations. Latin America, the Middle East, and Africa show growing awareness of infantile epileptic spasms syndrome, yet treatment success is often limited by delayed referral, affordability constraints, EEG access, supply-chain reliability, and shortages of pediatric epileptologists.

Key Group Insights

Within ASEAN, infantile spasms therapeutics demand is shaped by improving pediatric neurology capacity in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, but diagnostic access varies substantially between tertiary centers and community-level care. The GCC benefits from high health expenditure, tertiary hospitals, genetic testing adoption, and medical tourism hubs, supporting specialist-led management of rare pediatric epilepsies and faster access to advanced diagnostics.

The European Union offers the strongest regional framework for pharmacovigilance, pediatric research ethics, orphan-drug regulation, and cross-border regulatory consistency, while BRICS countries represent large birth cohorts and expanding neurology infrastructure constrained by variable diagnosis, reimbursement, and rural access. G7 markets remain central for innovation, evidence publication, guideline development, and premium therapy access. NATO is not a health purchasing bloc, but many member countries have advanced hospital systems, pediatric neurology networks, and collaborative research environments that indirectly support pediatric epilepsy care standards.

Key Country Insights

The United States leads commercialization through specialty neurology channels, payer-managed access, rare-disease coding infrastructure, and high-cost orphan therapy pathways, while Canada emphasizes evidence-based formulary review and province-level access. Mexico and Brazil show rising pediatric epilepsy awareness and expanding tertiary care, but referral speed, EEG availability, and out-of-pocket exposure remain barriers. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist epilepsy centers with national reimbursement systems and guideline-based care, whereas Russia faces access variability across regions and differences in specialist availability.

China, India, Japan, Australia, and South Korea are increasingly important for infantile spasms therapeutics. Japan and South Korea offer advanced diagnostic infrastructure, regulated specialty care, and strong hospital-based neurology services; China is strengthening rare-disease policy, pediatric neurology capacity, and tertiary hospital access; India presents large unmet need with uneven EEG availability and wide urban-rural differences; and Australia supports guideline-driven treatment through centralized pediatric neurology services, public hospital networks, and specialist referral pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize rapid-diagnosis pathways, caregiver education, and partnerships with pediatricians because early recognition directly affects treatment opportunity. Commercial teams should align messaging with guideline-supported outcomes, including spasm cessation, EEG response, relapse monitoring, etiology-specific treatment selection, and monitored safety.

Manufacturers can strengthen market access by generating real-world evidence on treatment timing, hospitalization burden, relapse, adverse events, visual monitoring, steroid-related complications, and developmental follow-up. Strategic investment should also focus on affordable formulations, digital referral tools, AI-assisted triage validation, caregiver support programs, and collaborations with epilepsy centers to improve trial enrollment in a rare and time-sensitive condition.

Research Methodology

This executive summary is based on triangulated secondary research from peer-reviewed neurology literature, clinical practice guidelines, regulatory databases, public health sources, clinical trial registries, reimbursement-policy references, and publicly available healthcare access documentation. Key sources include internationally recognized epilepsy classifications, pediatric neurology publications, and regulatory information from agencies such as the FDA, EMA, PMDA, and comparable national authorities.

The methodology applies a structured review of disease epidemiology, treatment standards, regulatory status, regional access conditions, clinical evidence, care-pathway dynamics, and stakeholder relevance. Insights are screened for clinical reliability, data recency, source credibility, geographic applicability, and commercial relevance to infantile spasms therapeutics while avoiding unverified assumptions, market sizing, or forecasting claims.

Conclusion

The infantile spasms therapeutics market is defined by urgent clinical need, concentrated specialty care, and high consequences of delayed treatment. Although the patient population is small, the value of effective therapy is substantial because early seizure control can influence developmental trajectory, relapse risk, caregiver burden, and long-term healthcare utilization.

Future leadership will depend on evidence-backed therapies, faster diagnosis, equitable access, safety monitoring, and stronger real-world data. Organizations that integrate clinical credibility with digital enablement, caregiver-centered support, and regional access strategies will be best positioned in this specialized pediatric epilepsy therapeutics landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Infantile Spasms Therapeutics Market, by Therapeutic Class
7.1. Introduction
7.2. Antiepileptic / Anticonvulsant Drugs (AEDs)
7.2.1. Vigabatrin
7.2.2. Levetiracetam
7.2.3. Topiramate
7.2.4. Zonisamide
7.2.5. Valproate
7.3. Hormonal Therapies
7.3.1. Adrenocorticotropic Hormone
7.3.2. Corticosteroids
7.4. Combination Therapies
7.4.1. ACTH + Vigabatrin
7.4.2. Steroids + AEDs
8. Infantile Spasms Therapeutics Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intramuscular
8.2.2. Intravenous
8.3. Oral
8.3.1. Solution
8.3.2. Tablet
9. Infantile Spasms Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Infantile Spasms Therapeutics Market, by Indication Type / Etiology
10.1. Introduction
10.2. Idiopathic Infantile Spasms
10.3. Symptomatic Infantile Spasms
10.4. Cryptogenic Infantile Spasms
11. Infantile Spasms Therapeutics Market, by Region
11.1. Asia-Pacific
11.2. Europe
11.3. North America
11.4. Latin America
11.5. Africa
11.6. Middle East
12. Infantile Spasms Therapeutics Market, by Group
12.1. NATO
12.2. G7
12.3. European Union
12.4. BRICS
12.5. ASEAN
12.6. GCC
13. Infantile Spasms Therapeutics Market, by Country
13.1. United States
13.2. China
13.3. Germany
13.4. Japan
13.5. India
13.6. United Kingdom
13.7. France
13.8. Canada
13.9. Australia
13.10. Brazil
13.11. Italy
13.12. Mexico
13.13. South Korea
13.14. Russia
13.15. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Actavis Pharma, Inc.
15.2. Aidarex Pharmaceuticals LLC
15.3. Amneal Pharmaceuticals NY LLC
15.4. Amzell B.V.
15.5. Anavex Life Sciences Corp.
15.6. Aurobindo Pharma Limited
15.7. A-S Medication Solutions
15.8. Bio-Pharm Solutions, Co., Ltd.
15.9. Carnegie Pharmaceuticals LLC
15.10. Catalent Pharma Solutions Limited
15.11. Catalyst Pharmaceuticals, Inc.
15.12. Cerecin, Inc.
15.13. Cerium Pharmaceuticals, Inc.
15.14. Chartwell RX, LLC
15.15. Dr. Reddy's Laboratories Limited
15.16. H. Lundbeck A/S
15.17. Hikma Pharmaceuticals USA Inc.
15.18. ICON PLC
15.19. Ipsen Biopharm Limited
15.20. Jazz Pharmaceuticals PLC
15.21. Lannett Company, Inc.
15.22. Lohxa
15.23. Mallinckrodt plc
15.24. Nordic Pharma, Inc.
15.25. Orphelia Pharma SAS
15.26. PAI Holdings, LLC
15.27. Pyros Pharmaceuticals, Incorporated
15.28. Radius Pharmaceuticals, Inc.
15.29. Remedy Repack Inc.
15.30. SK Life Science, Inc.
15.31. Upsher-Smith Laboratories, LLC
15.32. Veristat Spain S.L.
15.33. West Therapeutic Development, LLC
15.34. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 11. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL VIGABATRIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL VIGABATRIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL VIGABATRIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL LEVETIRACETAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL LEVETIRACETAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL LEVETIRACETAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TOPIRAMATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TOPIRAMATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TOPIRAMATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ZONISAMIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ZONISAMIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ZONISAMIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL VALPROATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL VALPROATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL VALPROATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ADRENOCORTICOTROPIC HORMONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ADRENOCORTICOTROPIC HORMONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ADRENOCORTICOTROPIC HORMONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ACTH + VIGABATRIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ACTH + VIGABATRIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ACTH + VIGABATRIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL STEROIDS + AEDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL STEROIDS + AEDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL STEROIDS + AEDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL SOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL SOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL IDIOPATHIC INFANTILE SPASMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL IDIOPATHIC INFANTILE SPASMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL IDIOPATHIC INFANTILE SPASMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SYMPTOMATIC INFANTILE SPASMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SYMPTOMATIC INFANTILE SPASMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SYMPTOMATIC INFANTILE SPASMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CRYPTOGENIC INFANTILE SPASMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CRYPTOGENIC INFANTILE SPASMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CRYPTOGENIC INFANTILE SPASMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 90. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 92. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 93. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 94. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 95. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 96. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 97. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 98. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 120. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 122. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 123. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 124. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 125. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 126. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 127. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 128. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 143. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 144. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 145. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 146. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 147. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 148. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 149. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 151. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 153. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 154. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 155. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 156. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 158. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 159. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 171. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 173. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 174. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 175. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 176. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 177. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 178. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 179. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 181. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 183. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 184. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 185. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 186. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 188. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 189. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 191. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 193. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 194. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 195. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 196. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 198. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 199. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 212. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 213. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 214. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 215. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 216. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 217. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 219. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 220. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 222. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 224. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 225. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 226. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 227. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 229. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 230. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 232. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 234. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 235. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 236. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 237. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 239. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 240. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 241. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 242. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 243. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 244. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 245. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 246. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 247. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 248. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 249. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 250. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 262. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 264. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 265. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 266. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 267. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 268. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 269. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 270. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 271. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 272. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 274. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 275. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 276. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 277. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 278. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 279. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 280. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 282. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 284. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 285. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 286. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 287. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 288. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 289. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 290. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 292. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 293. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 294. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 295. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 296. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 297. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 298. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 299. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 300. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 302. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 304. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 305. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 306. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 307. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 308. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 309. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 310. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 311. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INDICATION TYPE / ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 312. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 314. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC / ANTICONVULSANT DRUGS (AEDS), 2017-2032 (USD MILLION)
TABLE 315. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 316. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2017-2032 (USD MILLION)
TABLE 317. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. MEXICO INFANTILE SPASMS THER

Companies Mentioned

  • Actavis Pharma, Inc.
  • Aidarex Pharmaceuticals LLC
  • Amneal Pharmaceuticals NY LLC
  • Amzell B.V.
  • Anavex Life Sciences Corp.
  • Aurobindo Pharma Limited
  • A‑S Medication Solutions
  • Bio‑Pharm Solutions, Co., Ltd.
  • Carnegie Pharmaceuticals LLC
  • Catalent Pharma Solutions Limited
  • Catalyst Pharmaceuticals, Inc.
  • Cerecin, Inc.
  • Cerium Pharmaceuticals, Inc.
  • Chartwell RX, LLC
  • Dr. Reddy's Laboratories Limited
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals USA Inc.
  • ICON PLC
  • Ipsen Biopharm Limited
  • Jazz Pharmaceuticals PLC
  • Lannett Company, Inc.
  • Lohxa
  • Mallinckrodt plc
  • Nordic Pharma, Inc.
  • Orphelia Pharma SAS
  • PAI Holdings, LLC
  • Pyros Pharmaceuticals, Incorporated
  • Radius Pharmaceuticals, Inc.
  • Remedy Repack Inc.
  • SK Life Science, Inc.
  • Upsher‑Smith Laboratories, LLC
  • Veristat Spain S.L.
  • West Therapeutic Development, LLC
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 177 Million
Forecasted Market Value ( USD ) by 2032 $ 243.73 Million
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned34

Related Topics

Related Reports

Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type, Dosage, Route of Administration, Distribution Channel, End User, and Region 2026-2034 - Product Image

Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type, Dosage, Route of Administration, Distribution Channel, End User, and Region 2026-2034

  • Report
  • 135 Pages
  • Global
From
Infantile Spasm Therapeutics Market - Global Strategic Business Report - Product Image

Infantile Spasm Therapeutics Market - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Infantile Spasm Relief Medication Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Infantile Spasm Relief Medication Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 193 Pages
  • Global
From
West Syndrome Market Report 2026 - Product Image

West Syndrome Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Infantile Spasm Drug Market

Infantile Spasm (IS) is a rare neurological disorder that affects infants and young children. It is characterized by sudden, brief, and repetitive muscle contractions, usually in the form of jerking movements. Treatment for IS typically involves anticonvulsant drugs, such as vigabatrin, topiramate, and adrenocorticotropic hormone (ACTH). These drugs are used to reduce the frequency and severity of spasms, as well as to prevent further seizures. The Infantile Spasm Drug market is a subset of the Central Nervous System Drugs market. It is a small but growing market, driven by the increasing prevalence of IS and the need for effective treatments. The market is highly competitive, with a number of companies offering various drugs for the treatment of IS. Some of the major companies in the Infantile Spasm Drug market include Pfizer, Novartis, Sanofi, GlaxoSmithKline, and Merck. These companies offer a range of drugs for the treatment of IS, including vigabatrin, topiramate, and ACTH. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.